文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Aficamten与美托洛尔对梗阻性肥厚型心肌病运动能力的对比:MAPLE-HCM随机临床试验

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2026-01-01

MAPLE-HCM试验预设次要分析,纳入175例有症状梗阻性肥厚型心肌病患者,随机接受Aficamten或美托洛尔治疗24周,评估多个运动阶段指标。结果显示Aficamten在次极量运动通气效率、无氧阈、峰值负荷、运动后氧恢复及循环功率等方面均优于美托洛尔,支持其作为一线治疗。

要点

  • Aficamten组峰值VO2大幅改善(≥3.0 mL/kg/min)比例高于美托洛尔组(20.5% vs 3.7%,OR 6.8,95%CI 2.0-22.5)。
  • 美托洛尔组峰值VO2大幅下降(≥3.0 mL/kg/min)比例显著高于Aficamten组(20.7% vs 2.4%,OR 10.6,95%CI 2.6至∞)。

核心结论

  • 在有症状oHCM患者中,Aficamten单药治疗在促进多阶段运动适应方面优于美托洛尔。
  • 结果支持Aficamten作为oHCM的一线治疗。

研究设计与样本

  • MAPLE-HCM研究为3期、随机、活性对照试验的预设次要分析。
  • 2023年6月至2025年3月在北美、南美、欧洲、以色列及中国共71个中心开展。
  • 纳入有症状oHCM且存在运动不耐受客观证据(峰值氧摄取<100%预测值)的患者。
  • 随机1:1接受滴定Aficamten(5-20 mg/日)或匹配滴定美托洛尔(50-200 mg/日)治疗24周。
  • 共175例随机参与者,平均年龄57.7岁(SD 13.2),男性102例(58.3%);165例(94%)有核心实验室验证的运动试验数据。

临床怎么用

  • 对于有症状oHCM且运动不耐受的患者,Aficamten单药可改善多阶段运动指标。
  • Aficamten在改善运动能力方面优于美托洛尔,可考虑作为一线治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with obstructive hypertrophic cardiomyopathy (oHCM) endure life-altering exercise limitations. Current treatment guidelines recommend β-blockers as first-line therapy primarily based on expert opinion. The Metoprolol vs Aficamten in Patients with Left Ventricular Outflow Tract Obstruction on Exercise Capacity in HCM (MAPLE-HCM) trial characterizes comprehensive exercise response to aficamten monotherapy vs β-blockade (metoprolol). OBJECTIVE: To determine the effect of aficamten compared with metoprolol across all stages of exercise using 16 quantitative measures in individuals with oHCM. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of the MAPLE-HCM study, a phase 3, randomized, active-control trial conducted from June 2023 to March 2025 with data analyzed between May and July 2025 at 71 sites in North America, South America, Europe, Israel, and China. Patients with symptomatic oHCM with objective evidence of exercise intolerance (peak oxygen uptake [pVO2] <100% of predicted) were included. Those with a history of atrial fibrillation (paroxysmal or persistent), medical indication for β-blockers or calcium channel blockers prohibiting drug discontinuation, or intolerance or medical contraindication to β-blockers were excluded. INTERVENTION: Randomized 1:1 to titrated aficamten (5-20 mg daily) or matching titrated metoprolol (50-200 mg daily) for 24 weeks. MAIN OUTCOMES AND MEASURES: The main outcomes were submaximal exercise minute ventilation (VE)/carbon dioxide output (VCO2) slope and anaerobic threshold; peak exercise duration, workload, heart rate and heart rate reserve; and postexercise oxygen recovery rates; and composite variables, such as circulatory power. RESULTS: Of 175 randomized participants (mean [SD] age, 57.7 [13.2] years; 102 [58.3%] male), 165 (94%) had core laboratory-validated exercise tests at baseline and week 24. Compared with metoprolol, aficamten treatment improved multiple stages of exercise; including submaximal exercise VE/VCO2 slope (-2.8; 95% CI, -4.0 to -1.5; P < .001) and anaerobic threshold (76 mL/min; 95% CI, 41 to 111; P < .001); peak workload (8 watts; 95% CI, 3 to 13; P = .003); the time required for VO2 to recover by 12.5% postexercise (-11 seconds; 95% CI, -16 to -5; P < .001); and circulatory power (819 mm Hg × mL/min per kg; 95% CI, 569 to 1070; P < .001). Large improvements (≥3.0 mL/kg/min) in peak VO2 were more common with aficamten compared with metoprolol (17 [20.5%] vs 3 [3.7%], respectively; odds ratio, 6.8; 95% CI, 2.0 to 22.5; P < .001). In contrast, large reductions in peak VO2 (≥3.0 mL/kg/min) were significantly more common with metoprolol than aficamten (17 [20.7%] vs 2 [2.4%], respectively; odds ratio, 10.6; 95% CI, 2.6 to ∞; P < .001). CONCLUSIONS AND RELEVANCE: This prespecified analysis of MAPLE-HCM demonstrated monotherapy with aficamten was superior to metoprolol in promoting adaptation to multiple phases of exercise in patients with symptomatic oHCM and supports aficamten as first-line therapy for oHCM. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05767346.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Lewis GD, Garcia-Pavia P, Masri A, et al. Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 42307914. doi:10.1001/jamacardio.2026.1730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。